reported (< 1%). KYPROLIS can cause elevations of serum transaminases and bilirubin. Withhold
KYPROLIS in patients experiencing Grade 3 or greater elevations of transaminases, bilirubin, or other
liver abnormalities until resolved or returned to baseline. After resolution, consider if restarting
KYPROLIS is appropriate. Monitor liver enzymes frequently [see Dosage and Administration and
Adverse Reactions]. Embryo-fetal Toxicity. KYPROLIS can cause fetal harm when administered to a
pregnant woman based on its mechanism of action and findings in animals. There are no adequate and
well‑controlled studies in pregnant women using KYPROLIS. Carfilzomib caused embryo‑fetal toxicity in
pregnant rabbits at doses that were lower than in patients receiving the recommended dose. Females of
reproductive potential should be advised to avoid becoming pregnant while being treated with KYPROLIS.
If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the
patient should be apprised of the potential hazard to the fetus [see Use in Specific Populations].
ADVERSE REACTIONS: The following adverse reactions are discussed in greater detail in other sections
of the labeling:
• Cardiac Arrest, Congestive Heart Failure, Myocardial Ischemia [see Warnings and Precautions]
• Pulmonary Hypertension [see Warnings and Precautions]
• Pulmonary Complications [see Warnings and Precautions]
• Infusion Reactions [see Warnings and Precautions]
• Tumor Lysis Syndrome [see Warnings and Precautions]
• Thrombocytopenia [see Warni